GlassScriptPhysician profile
Mary P Mcmanmon
NPI 1255363172
$2,766.55
in general payments reported to CMS, 2019-2025
22 companies · $367 in 2025
The $367 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $117 · 2021: $511 · 2022: $690 · 2023: $457 · 2024: $330 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,153.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $400.70 | 2021-2025 | |
| Glaxosmithkline, LLC. | $308.43 | 2019-2025 | Trelegy Ellipta |
| Mylan Specialty L.P. | $251.39 | 2019-2024 | Yupelri |
| Baxter Healthcare | $241.48 | 2022 | |
| Lilly USA, LLC | $212.55 | 2021-2024 | Jardiance, Emgality, Mounjaro |
| Merck Sharp & Dohme LLC | $183.16 | 2020-2025 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.48 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $175.88 | 2021-2023 | |
| Gilead Sciences, INC. | $135.46 | 2019-2025 | |
| Amgen INC. | $119.72 | 2023-2025 | Repatha, Otezla, Repatha |
| Dexcom, INC. | $113.04 | 2021-2024 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $84.87 | 2019-2023 | Uzedy |
| Abbott Laboratories | $76.59 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Welch Allyn | $63.33 | 2021 | |
| Sanofi Pasteur INC. | $44.87 | 2019-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.19 | 2024-2025 | Caplyta |
| Aimmune Therapeutics, INC. | $26.54 | 2025 | Zenpep |
| Otsuka America Pharmaceutical, INC. | $23.90 | 2024 | Rexulti |
| Amarin Pharma, INC. | $22.98 | 2020 | |
| Lundbeck LLC | $21.79 | 2024 | Rexulti |
| Sobi, INC | $18.75 | 2019 | |
| Insulet Corporation | $17.45 | 2023 | Omnipod |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Mcmanmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.